Physician-read biotech intelligence
Every major GI and liver trial readout and FDA decision, scored 0 to 10 for clinical meaning by a specialist, the day it happens.
Public information only. Clinical analysis, not investment advice.
Maintenance trial · Reviewed by a gastroenterologist
Example layout. Live Reads link every claim to its public source.
Upcoming GI catalysts
A preview of the GI and liver events we track. Each score is a draft until the reviewing physician signs it.
| Drug · company | Indication | Event | Timing | Score | Source |
|---|---|---|---|---|---|
| Obefazimod (oral)Abivax · ABVX | Ulcerative colitis | NDA submission to FDA | Late Q4 2026 (planned) | 7/10 | Abivax |
| TezepelumabAmgen · AMGN / AstraZeneca · AZN | Eosinophilic esophagitis | Phase 3 CROSSING data; filing timing not stated | Data out Oct 20, 2026 | 8/10 | Amgen |
| Vedolizumab IVTakeda · TAK | Pediatric UC and Crohn's, age 2+ | FDA decision | Q1 2027 | Read at decision | Takeda |
| ResmetiromMadrigal · MDGL | Compensated MASH cirrhosis | MAESTRO-NASH OUTCOMES results | Not disclosed | Read at readout | 10-Q |
| ObefazimodAbivax · ABVX | Crohn's disease | Phase 2b ENHANCE-CD topline | Mid-2027 | Read at readout | 6-K |
Timing as stated by each company. Checked November 2026. Public information only, not investment advice.
Same news, two readings
What a catalyst calendar shows
AMGN / AZN · Tezepelumab · Eosinophilic esophagitis
Phase 3 CROSSING met both co-primary endpoints at week 24. Data presented at UEG Week, October 2026.
Accurate, and almost no help deciding whether the result matters to patients or prescribers.
Amgen / AstraZeneca · Reviewed by a gastroenterologist
Figures from Amgen's October 2026 release. Draft score, pending physician sign-off.
Where ReadoutRx fits
ReadoutRx is the fast clinical take on every readout. It sits alongside surveys and expert calls rather than replacing them.
| Feature | Catalyst calendar | Expert call | Physician survey report | ReadoutRx |
|---|---|---|---|---|
| Speed after the news | Same day | Days to book | Monthly or quarterly | Within 24 hours |
| Clinical verdict | None | One physician's view | Aggregated opinions | Signed, scored 0–10 |
| Comparable across drugs | No | No | Within one report | Yes, one fixed rubric |
| Public track record | No | Not usually | Not usually | Every past score |
| Typical cost | Free to low | About $1,000+ per hour | Enterprise contract | From $0 |
How it works
01 Detect
Trial registries, SEC filings, FDA records and journals are scanned daily, including quiet changes to a trial's endpoints or timelines.
02 Draft
Each event gets a draft with source links, then an automated check of every date, number and ticker against the original.
03 Review
A practicing physician in the field corrects the draft, sets the score and adds the clinical verdict.
04 Deliver
Alerts within hours, a searchable archive, and every past score kept public next to what happened.
Inside a Physician Read
The same structure every time, so a hepatology readout and an oncology readout can be compared in seconds.
Track record
When approvals, labels and real-world uptake arrive, we add them beside the original score, including when we were wrong. That record is what makes a score worth trusting.
| Scored | Drug and event | Score | What happened next | Status |
|---|---|---|---|---|
| Nov 2026 | ObefazimodUC maintenance, Phase 3 | 7/10 | NDA submission planned for late Q4 2026 | Awaiting outcome |
| Nov 2026 | TezepelumabEosinophilic esophagitis, Phase 3 | 8/10 | Regulatory filing not yet announced | Awaiting outcome |
Draft scores shown as a preview. The public record starts with the first published digest.
Who signs the Reads
Internal medicine physician completing subspecialty training in gastroenterology at a tertiary academic center, with daily work in endoscopy and complex GI cases.
Disclosures: [none]. Every reviewer completes a conflict-of-interest check before each Read.
A specialist in another field? Apply to review for ReadoutRx.
What you get, and when
The weekly digest: the week's catalysts and one full Physician Read.
A Read and score for each major GI readout or FDA decision, for Pro members.
A track-record update, adding new outcomes beside past scores.
Coverage of DDW, EASL, UEG Week, ACG and AASLD's The Liver Meeting.
Coverage
Founded by a gastroenterologist. A new area opens only when a practicing specialist in that field joins as its reviewer.
Pricing
Start free. Upgrade when you want every Read.
For curious investors and students.
For active biotech investors.
For funds, family offices and analysts.
Paid plans open after launch. Join the free digest to hear first.
Every Read is built from published filings, registries and papers. Nothing confidential, ever.
Reviewers never cover a trial or company they work on, consult for or hold.
We judge the medicine. No buy or sell calls, no price targets.
Every past score stays public, next to what actually happened.
Learn the language
New to biotech catalysts? Start here. Every Read uses these words the same way.
A calendar lists dates and headlines. An expert call gives one physician's view, booked and paid by the hour. ReadoutRx gives every major readout a signed, scored clinical verdict within a day, and keeps every score public so you can judge our record.
Software drafts each brief from public sources. A practicing specialist in the relevant field reviews, corrects and signs it before it reaches you.
No. We assess the clinical meaning of results. Investment decisions are yours; consider a licensed advisor.
A published rubric adds points for endpoint quality, effect versus standard of care, safety and practicality. Read the full method.
Yes. Pro will be month to month, cancelled from your account in one step.
The free weekly digest: this week's catalysts and one full Physician Read.
Scoring method
Every Physician Read scores a result from 0 to 10 by adding four parts. The rubric is fixed so scores stay comparable over time, and each Read notes how mature the data are: a topline press release, a full publication or a regulatory decision. When full data appear, we re-score and keep both scores visible.
| Part | Points | Low | Middle | High |
|---|---|---|---|---|
| Endpoint quality | 0–3 | Exploratory or patient-reported only | Accepted surrogate | Hard endpoint regulators respect |
| Versus standard of care | 0–3 | No better than existing options | Comparable to current advanced therapies | Clearly better, or works where others fail |
| Safety | 0–2 | New serious signal | Known, manageable class effects | Clean profile at trial duration |
| Practicality and adoption | 0–2 | Burdensome, narrow population | Some barriers | Easy to use, broad population |
The score measures clinical significance only. It is not a prediction of stock performance, regulatory outcome or commercial sales, and it is never a recommendation to buy or sell a security.
Archive
Every Read we publish, newest first, with the score, its four parts and every source. Scores stay here when outcomes arrive, including when we were wrong.
Loading Reads…
Legal
Draft pending legal review. Bracketed details are filled in before launch.
ReadoutRx is operated by [operator name], [business registration number], [address], Israel. Contact: readoutrx@gmail.com.
Summaries of publicly available biotech and clinical-trial information and physician commentary on its clinical meaning, including Physician Reads and clinical-meaningfulness scores.
Nothing we publish is investment advice or a recommendation to buy or sell any security. We do not consider your personal financial situation. Scores measure clinical significance only. You alone are responsible for your investment decisions.
Our content discusses drugs and trial results in general terms. It is not medical advice for any individual and creates no doctor–patient relationship.
We work from public sources and check our content carefully, but it may contain errors or become outdated. The service is provided as is, and clinical opinions may turn out to be wrong.
All content is based on publicly available information. We do not use or seek confidential or material non-public information. If you believe content contains such information, contact us immediately.
Paid plans renew each month or year until cancelled, and access continues to the end of the paid period. Payments are processed by [payment provider]. [Refund policy.]
Subscriptions are for personal use, or internal use under an Institutional plan. Do not resell, republish or redistribute our content, or use it to train AI models, without written permission. Short quotations with attribution are fine.
To the extent the law allows, ReadoutRx and its contributors are not liable for investment losses or indirect damages from use of the service. Our total liability is limited to fees paid in the 12 months before a claim.
These Terms are governed by the laws of the State of Israel, with exclusive jurisdiction in the competent courts of [city].
Legal
Draft pending legal review. Bracketed details are filled in before launch.
ReadoutRx, operated by [operator name], [address], Israel, controls your personal data. Contact: readoutrx@gmail.com.
Your email address, and your name or organization if you give them; messages and survey answers you send; payment status from our payment provider, never your full card number; and basic email and website statistics such as opens, clicks and approximate country.
To send the content you subscribed to, manage subscriptions and support, improve our content using aggregated statistics, and meet tax and legal duties. Your email is required to receive the service; everything else is optional.
We do not sell or rent personal data or share it for third-party advertising.
Only providers that process it for us: [newsletter platform], [payment provider], [website host] and [analytics provider]. Some are outside Israel, including in the United States.
While you are subscribed and up to [12] months after you unsubscribe, except billing records kept as Israeli tax law requires.
You can ask to see, correct or delete your data, or withdraw consent, by emailing readoutrx@gmail.com. Every email has a one-click unsubscribe link. In the EU or UK you may complain to your data protection authority; in Israel, to the Privacy Protection Authority.
The service is not intended for anyone under 18.